Can Euro Biom source discontinued or hard-to-find branded comparators?

Often, yes. Through our network of authorised manufacturers and licensed wholesalers across the UK and EU, we have access to brands no longer in active commercial supply or available only in restricted markets. We never source from grey-market channels. If a product cannot be obtained through compliant routes, we tell you at the feasibility stage and discuss alternative comparator strategies.

How is provenance verified for comparator supply?

Every comparator is traced from authorised manufacturer through licensed wholesale to Euro Biom, with documentary evidence at each step. We hold MHRA WDA(H) 59239, source only from MHRA-licensed or EU GDP-licensed counterparties, and provide full chain of custody, manufacturer batch records and Certificate of Analysis with the supply. Provenance documentation is structured to support sponsor and CRO regulatory inspections.

What information do you need for a comparator quote?

To respond accurately we need the comparator name (INN and brand if specified), required country of origin if protocol-defined, strength and dosage form, total trial quantity and per-site quantity, minimum acceptable expiry dating, target delivery date and destination country, and any blinding or packaging requirements. If you have a draft sourcing brief or protocol-extracted specification, that accelerates our response.

Comparator Sourcing

Clinical Trial
Comparator Drug
Sourcing UK

Euro Biom is an MHRA WDA-licensed wholesale distributor sourcing branded comparators, Reference Listed Drugs and biosimilar references for the control arms of clinical trials. Verified provenance, single-batch supply and blinding-ready packaging coordination.

MHRA WDA Licence No. WDA(H) 59239Granted 17 March 2026

Submit a Comparator Brief Full Clinical Trial Supply →

⚡ Same-day response to every brief · Mon-Fri 09:00-18:00 · WhatsApp us

What is a Comparator Drug

The medicine in the
control arm.

A comparator drug is the medicine used to control the experimental arm of a clinical trial. The investigational product is measured against it for efficacy, safety or pharmacokinetic profile. Without a defensible comparator, the trial result has no benchmark.

Comparators take several forms. An active comparator is an approved drug already in clinical use for the same indication. A Reference Listed Drug (RLD) is the specific approved product against which generic or biosimilar candidates must demonstrate equivalence under FDA, MHRA or EMA frameworks. A placebo serves as control in studies where no approved active treatment exists or where the protocol requires it.

In every case, the comparator must be the exact branded product specified by the protocol. Substitutions are not permitted without protocol amendment. This precision requirement is what makes comparator sourcing fundamentally different from commercial wholesale supply.

Active Comparator Reference Listed Drug Branded Comparator Single-Batch Supply

"A comparator is not a substitutable commodity. It is a specific batch of a specific brand from a specific origin, defined by protocol. Sourcing it is a regulated documentation exercise, not a procurement transaction."

Why Comparator Sourcing Is Hard

Six Reasons Conventional
Channels Cannot Deliver

Commercial pharmaceutical wholesale is optimised for high-volume, recurring distribution. Clinical trial comparator demand is the opposite shape.

Small, Irregular Volumes

A trial may need 200 packs of one product across 18 months. Commercial wholesalers do not configure for orders of that shape; they prioritise large recurring contracts. The economics push comparator demand to the bottom of the queue.

Brand-Specific Requirements

The protocol names a single brand from a single country of origin. Generic substitution is not acceptable. Even minor differences in formulation, excipients or manufacturer site can invalidate the comparison and the trial.

Batch Consistency

Many protocols require a single batch across all trial sites or a tightly controlled set of batches with documented overlap. Sourcing must be planned around manufacturing campaigns, not pulled from rolling commercial stock.

Expiry Dating Across Trial Duration

A 36-month trial needs comparator with at least 36 months of remaining shelf life at the point of supply, plus contingency. Stock with three months expiry, fine for commercial use, is useless for trial supply.

Blinding and Packaging Demands

Blinded studies require over-encapsulation, matched placebo, label translation and randomised kit assembly. None of this is possible without licensed packaging coordination, sourcing schedule alignment and chain-of-custody documentation.

Provenance and Documentation

Sponsor regulatory inspections expect a documented chain from authorised manufacturer through licensed wholesale to the trial site. Grey-market or unverifiable sourcing creates inspection risk that can derail the entire study.

The Euro Biom Solution

Comparator sourcing built
for trial-grade specification.

Our model is calibrated to the precision and documentation demands of clinical research, not to the volume economics of commercial supply.

MHRA-Verified Provenance

Every comparator is sourced through MHRA-licensed manufacturers or EU GDP-licensed wholesalers. We never use grey-market channels, parallel imports of unverified origin or unauthorised intermediaries. Documentary chain of custody is provided from manufacturer through to delivery.

WDA(H) 59239 | GDP-licensed counterparties only

Single-Batch and Multi-Batch Sourcing

Whether the protocol calls for single-batch supply across all sites or a controlled set of batches with documented overlap, we plan the sourcing to match. We confirm batch availability with the manufacturer or licensed wholesaler before quoting, not after order placement.

Batch confirmation before quotation

Expiry Dating Aligned to Trial Duration

We negotiate stock with the longest available expiry. For 24-month and 36-month studies, we work with the manufacturer's release calendar to secure freshly released batches and document the expiry profile so trial supply remains valid throughout the study with contingency margin.

Trial-duration expiry as standard

Blinding-Ready Packaging Coordination

Where the protocol requires over-encapsulation, matched placebo or randomised kit assembly, we coordinate with MHRA MIA(IMP)-licensed packaging partners. We deliver to the packager, the packager performs the licensed reconfiguration, and we maintain wholesale documentation throughout.

Licensed packaging partners coordinated

Common Comparator Types

What We Source

Comparator demand falls into a small number of categories. Each has its own sourcing pattern.

💊

Innovator Branded Comparators

The originator branded product still under patent protection or marketed by the originator. Used as the active control in head-to-head efficacy and safety studies. Typically the most demanding sourcing pattern because the originator may restrict commercial channels.

📋

Reference Listed Drugs (RLDs)

The specific approved product designated by FDA, MHRA or EMA against which generic or biosimilar candidates must demonstrate equivalence. RLD selection is regulator-defined and substitutions are not permitted.

⏳

Off-Patent Originals

Originator brands of off-patent molecules. Still required as comparators in some study designs, particularly in real-world evidence research and post-marketing surveillance. Sourcing depends on whether the originator continues to manufacture the brand.

🧪

Biosimilar Reference Products

Originator biologics used as the reference for biosimilar comparative analytical, pharmacokinetic and clinical studies. Cold-chain handling and batch-matching for analytical comparison are central to specification.

🌡️

Standard-of-Care Drugs

Established treatments used as the active control representing standard of care in the studied indication. The specific product may vary by region and protocol may name multiple acceptable variants.

⚪

Placebo Coordination

Where placebo is required, we coordinate manufacture through MHRA-licensed packaging partners with matched appearance, flavour and presentation to support blinding integrity. Placebo manufacture is performed by licensed sites; we coordinate sourcing and supply.

How It Works

From Brief to
Documented Delivery

A four-step process built for the documentation, traceability and timing demands of clinical research.

Step 01

Sourcing Brief

You send the comparator name, required country of origin, brand specification, total volume, per-site quantity, minimum expiry dating, target dates and any blinding or packaging requirements. We confirm feasibility within the working day.

Step 02

Verification

We identify the licensed sourcing route, confirm batch availability with the manufacturer or wholesaler, secure target expiry dating and document the chain. Quotation includes documentary evidence of provenance before order placement.

Step 03

Documentation

On confirmation we prepare the full GDP documentation pack including Certificate of Analysis, manufacturer batch records, chain of custody, transport and temperature records, and any country-specific export or import paperwork.

Step 04

Blinded Packaging or Direct Supply

Where blinded packaging is required, comparator is delivered to the MHRA MIA(IMP) partner for over-encapsulation, kit assembly and randomised distribution. For direct trial site supply, product ships under continuous temperature monitoring with full documentation pack.

Where Comparator Demand Concentrates

Therapeutic Areas
We Cover Most Often

Comparator demand is heaviest where active research is most concentrated and where active-controlled trial designs are standard.

🔬

Oncology

The largest single source of comparator demand. Targeted therapies, immuno-oncology agents and cytotoxics used as active controls in head-to-head efficacy trials.

🧬

Immunology

Monoclonal antibodies and biologics in autoimmune disease research. Frequent reference biologic supply for biosimilar studies in rheumatoid arthritis, IBD and psoriasis.

🫀

Cardiovascular

Anticoagulants, novel oral anticoagulants, statins and antihypertensives used as active controls in cardiovascular outcome and safety studies.

🧠

CNS and Neurology

Antipsychotics, antidepressants, antiepileptics and MS disease-modifying therapies used as active comparators in CNS efficacy and switching trials.

💉

Diabetes and Endocrinology

Insulin analogues, GLP-1 agonists and SGLT2 inhibitors used as comparators in head-to-head glycaemic control and weight outcome studies.

🧫

Rare Disease

Low-volume comparator sourcing for rare disease research. Often the hardest sourcing because commercial supply is limited and the originator may restrict access.

Submit a Comparator Sourcing Brief

Send us the protocol-defined specification. We assess feasibility, identify the licensed sourcing route and respond the same working day with documentary evidence of provenance and indicative timeline.

Submit a Comparator Brief WhatsApp Us Directly

Frequently Asked Questions

Comparator Drug Sourcing, Explained

Common questions from clinical trial supply leads, sponsor regulatory teams and CRO sourcing managers.

What is a comparator drug in a clinical trial?

A comparator is the medicine in the control arm of a trial, used to measure the investigational treatment against. It can be an active control, a Reference Listed Drug for bioequivalence and biosimilar work, or a placebo where no approved active treatment exists.

Why is comparator sourcing harder than commercial supply?

Trial volumes are small and irregular, the protocol specifies a single brand and country of origin, batches must be consistent across trial duration, expiry dating must cover the full study, and blinding may demand specialist packaging. Commercial wholesale is built for the opposite shape of demand.

Can you source discontinued or hard-to-find branded comparators?

Often, yes. Through licensed manufacturers and EU GDP wholesalers we have access to brands no longer in active commercial supply. We never source from grey-market channels. If a product cannot be obtained compliantly, we tell you at the feasibility stage.

Do you provide blinded over-encapsulation or matched placebo?

Yes, through MHRA MIA(IMP)-licensed packaging partners. We source the comparator and deliver to the licensed packager, who performs over-encapsulation, matched placebo manufacture and blinded kit assembly. Euro Biom retains the wholesale supply documentation throughout.

How is provenance verified?

Every comparator is traced from authorised manufacturer through licensed wholesale to Euro Biom. We provide chain of custody, manufacturer batch records and Certificate of Analysis with every supply. Sourcing is restricted to MHRA WDA-licensed and EU GDP-licensed counterparties.

What information do you need for a quote?

Comparator name (INN and brand), required country of origin, strength and dosage form, total volume, per-site quantity, minimum expiry dating, target delivery date, destination country and any blinding or packaging requirements. Protocol-extracted briefs accelerate response.

Can you supply biosimilar reference products?

Yes. Reference biologics for biosimilar comparative analytical, PK and clinical studies are sourced through MHRA and EU GDP channels with cold-chain handling. Batch-matching for analytical work is coordinated with the manufacturer where the protocol requires it.

Related Resources

Further reading for clinical trial supply leads, sponsors and CROs.

Service

Clinical Trials Supply UK

IMPs, comparators, ancillaries →

Capability

Cold-Chain Pharmaceutical Supply UK

Validated temperature control →

Service

Named Patient Medicine Supply UK

Hospital unlicensed sourcing →

Compliance